Ozempic vs Wegovy

If you have looked into GLP-1 medications at all, you have probably noticed that Ozempic and Wegovy come up almost interchangeably — and then someone insists they are completely different. Both are right, in a sense. The single most useful thing to understand is this: Ozempic and Wegovy are the same drug. Both are semaglutide, both are made by Novo Nordisk, and both are once-weekly injections (with newer oral versions now on the market too). What separates them is not chemistry. It is the label, the dose, and the way the US healthcare system pays for them.

That distinction is not a technicality. It decides which one a doctor can prescribe you, whether your insurance will cover it, and what you will pay if it won’t.

Same molecule, two brands

Semaglutide is a GLP-1 receptor agonist — a synthetic peptide that mimics a gut hormone your body releases after eating. It slows stomach emptying, blunts appetite, and improves how the body handles blood sugar and insulin. Novo Nordisk holds the patent and sells that one molecule under more than one brand name, each developed and approved for a different purpose.

Ozempic came first, approved in the US in 2017 for type 2 diabetes. Wegovy followed in 2021, approved specifically for chronic weight management. Same active ingredient, different packaging, different approved indication, and — importantly — a different maximum dose. There is also Rybelsus, the original once-daily oral semaglutide tablet for diabetes, and as of 2025 an oral Wegovy pill approved for weight management. But when people say “Ozempic vs Wegovy,” they almost always mean the two weekly injection pens, so that is the comparison this page centers on.

Note: Because the drug is the same, you should never take Ozempic and Wegovy together. Doubling up on semaglutide doesn’t double the benefit — it stacks the dose and the side effects.

What each one is approved to do

This is where the brands genuinely diverge, and it is the heart of the comparison.

Ozempic is FDA-approved for adults with type 2 diabetes — to improve blood sugar control alongside diet and exercise. Its approved uses have expanded over the years to include reducing the risk of major cardiovascular events in people who have type 2 diabetes and established heart disease, and more recently to slow kidney disease progression in certain patients with type 2 diabetes. What it is not approved for is weight loss. Plenty of people lose weight on it, but that is not its label.

Wegovy is FDA-approved for chronic weight management in adults with obesity (a BMI of 30 or higher) or with overweight (BMI of 27+) plus a weight-related condition, and in adolescents 12 and older with obesity. Its label has also grown: in March 2024 Wegovy became the first weight-loss drug approved to reduce the risk of major cardiovascular events such as heart attack and stroke in adults with overweight or obesity and known heart disease, and it has since picked up an approval related to MASH (metabolic dysfunction-associated steatohepatitis, a serious liver condition). Wegovy is not approved to treat diabetes, even though it lowers blood sugar.

So the clean summary is: Ozempic is the diabetes brand. Wegovy is the weight-management brand. A person with type 2 diabetes who also wants to lose weight sits in the overlap, which is exactly where prescribing decisions get nuanced.

The dose difference — and why it matters

Both pens titrate upward slowly over a couple of months to let the body adjust, but they top out in different places. The approved maintenance ceiling for Ozempic is 2.0 mg once weekly. Wegovy’s standard maintenance dose is 2.4 mg once weekly (with a 1.7 mg option for people who can’t tolerate the full amount). In March 2026 the FDA approved a higher-strength version, Wegovy HD at 7.2 mg, for adults with obesity — a meaningful escalation in available dose.

These are official label figures, not a self-dosing recipe: the actual dose, titration pace, and whether you ever reach the maximum are decisions a prescriber makes for you individually based on your response and tolerance. The point for this comparison is simply that Wegovy’s approved range runs higher than Ozempic’s, and that higher dose is part of why Wegovy carries the weight-loss indication while Ozempic doesn’t.

Effectiveness: what the trials actually show

Because dose drives effect, the two brands produce different average results — but read this carefully, because the comparison is between doses, not between two different drugs.

The diabetes trials behind Ozempic (the SUSTAIN program) used lower doses and produced solid blood-sugar improvements with modest weight loss as a welcome side effect. The weight-loss trials behind Wegovy (the STEP program) used the 2.4 mg dose and showed average weight reductions in the mid-teens as a percentage of body weight over roughly a year and a half — figures that approach what some bariatric procedures achieve. The newer 7.2 mg Wegovy HD pushed average weight loss higher still in its trial.

The honest takeaway is that semaglutide at a higher dose produces more weight loss than semaglutide at a lower dose. That is unsurprising. It is also why “just use Ozempic for weight loss” is a real but imperfect strategy — at Ozempic’s lower ceiling, the average weight loss is typically smaller than what Wegovy delivers at 2.4 mg.

Cost and insurance: where the brands really split apart

For most Americans, the deciding factor between these two isn’t biology — it’s the bill.

List prices are high for both. Wegovy’s list price is around $1,349 per package, and Ozempic’s lists in the rough range of $935 to roughly $1,000 per month depending on the source and dose. Almost nobody pays the sticker, but the sticker shapes everything downstream. Novo Nordisk has signaled plans to bring list prices down substantially over 2026, with timing still being worked out.

If you have commercial insurance, coverage hinges on indication. Ozempic is widely covered for type 2 diabetes (usually after a prior authorization confirming the diagnosis), and Novo Nordisk’s savings card can knock many diabetic patients’ out-of-pocket cost down toward $25 or even near $0. Wegovy coverage for weight loss is far more variable — many plans exclude weight-loss drugs entirely, while others cover Wegovy with a savings card bringing copays toward $0–$25 for those who qualify. This is the crux of the off-label problem: a doctor can write Ozempic for weight loss, but if there’s no diabetes diagnosis, the insurer typically won’t pay, and you’re back to cash pricing.

If you’re paying cash, Novo Nordisk’s NovoCare direct self-pay channel has become the reference point. The standard self-pay price was lowered to $349 per month for most Wegovy and Ozempic doses (Wegovy HD higher, around $399), with periodic lower introductory pricing for new patients on the starting doses. Telehealth platforms increasingly offer subscription access to brand semaglutide at these self-pay rates.

If you have Medicare, Ozempic is covered under Part D for type 2 diabetes, with out-of-pocket costs that have come down under recent drug-pricing reforms. Wegovy’s Medicare picture is narrower and tied to specific approved uses such as cardiovascular risk reduction rather than weight loss broadly — an area where federal policy is genuinely in flux, so it’s worth confirming current status when you’re deciding.

Cost is detailed enough that it gets its own pages — see the Wegovy and Ozempic cost guides linked below — but the headline is that the same molecule can cost you $0 or well over a thousand dollars a month depending entirely on which brand, which indication, and which payer.

Side effects and safety — shared, by definition

Same drug means same safety profile. Both carry the identical boxed warning about a risk of thyroid C-cell tumors seen in rodent studies, and both are not for people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Both share the common gastrointestinal effects — nausea, vomiting, diarrhea, constipation — that are most pronounced when the dose increases. Both carry the same rarer but serious risks, including pancreatitis, gallbladder problems, kidney injury from dehydration, and worsening of pre-existing diabetic eye disease.

The one practical asymmetry: because Wegovy is dosed higher, side effects tend to show up more often and more strongly on Wegovy than on Ozempic. Same categories of effect, different frequency.

Which one applies to you

You don’t really choose between Ozempic and Wegovy the way you’d choose between two unrelated products. In practice your situation chooses for you:

• Type 2 diabetes is the main issue → Ozempic is the on-label, typically-covered route, with weight loss as a likely bonus.
• Weight management with no diabetes → Wegovy is the on-label option, and the one insurers are willing (when they cover GLP-1s at all) to approve for that purpose.
• Both diabetes and significant excess weight → this is the genuine judgment call, and it belongs with a prescriber weighing your glucose control, cardiovascular and kidney risk, weight goals, and what your plan will actually pay for.

None of this is a decision to make from a website. Semaglutide is a prescription medicine in every legitimate form, and the right brand, dose, and titration are individualized by a licensed provider who can evaluate you. This site does not sell, supply, or prescribe it — what it can do is help you walk into that conversation understanding that you’re really comparing two labels on one drug, and that the deciding question is usually “which indication will my coverage recognize?”